Role of favipiravir in the treatment of COVID-19.
Anti-viral
Clinical guidelines
In vitro
Pharmacokinetic
Viral clearance
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
03
08
2020
revised:
23
10
2020
accepted:
23
10
2020
pubmed:
2
11
2020
medline:
20
1
2021
entrez:
1
11
2020
Statut:
ppublish
Résumé
The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the researchers to strive to develop drugs or vaccines to prevent or halt the progression of this ailment. To hasten the treatment process, repurposed drugs are being evaluated. Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2. It has a wide therapeutic safety margin indicated by a wide CC50/EC50 ratio for a high dose. From the clinical studies in COVID-19, it has shown rapid viral clearance as compared to lopinavir/ritonavir (LPV/RTV) and superior recovery rate than umifenovir. Overall, favipiravir has shown promising results in clinical studies in China, Russia, and Japan, and more trials are underway in multiple countries, including USA, UK, and India. Recently, treatment guidelines from many countries and some states from India have included favipiravir in the treatment protocol. This review provides insights into the evidence-based evolving role of favipiravir in the management of COVID-19 infection with emphasis on benefits of initiating an early antiviral therapy with special focus on favipiravir, its pharmacodynamic, pharmacokinetic, in vitro, clinical data, and inclusion in the treatment protocols of COVID-19.
Identifiants
pubmed: 33130203
pii: S1201-9712(20)32273-6
doi: 10.1016/j.ijid.2020.10.069
pmc: PMC7831863
pii:
doi:
Substances chimiques
Amides
0
Antiviral Agents
0
Pyrazines
0
favipiravir
EW5GL2X7E0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
501-508Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Antiviral Res. 2018 May;153:85-94
pubmed: 29524445
Infez Med. 2020 Ahead of print Jun 1;28(2):198-211
pubmed: 32335561
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
N Engl J Med. 2020 Feb 20;382(8):760-762
pubmed: 31978944
Sci Adv. 2020 Nov 20;6(47):
pubmed: 33097472
Clin Pharmacokinet. 2016 Aug;55(8):907-23
pubmed: 26798032
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
J Intern Med. 2020 Jul;288(1):128-138
pubmed: 32220033
Antimicrob Agents Chemother. 2020 Nov 17;64(12):
pubmed: 32958718
Clin Infect Dis. 2021 Dec 6;73(11):e4197-e4205
pubmed: 32603425
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463
pubmed: 28769016
BMC Med. 2020 Jun 25;18(1):191
pubmed: 32586336
PLoS One. 2013 Jul 10;8(7):e68347
pubmed: 23874596
Disaster Med Public Health Prep. 2015 Feb;9(1):79-81
pubmed: 25544306
Curr Opin Infect Dis. 2019 Apr;32(2):176-186
pubmed: 30724789
Antibiotics (Basel). 2022 Jun 15;11(6):
pubmed: 35740211
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Curr Biol. 2020 Apr 20;30(8):1578
pubmed: 32315626
Nat Commun. 2020 Sep 17;11(1):4682
pubmed: 32943628
EBioMedicine. 2020 Aug;58:102916
pubmed: 32711256
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2790
pubmed: 24722586
Clin Infect Dis. 2016 Nov 15;63(10):1288-1294
pubmed: 27553371
Clin Pharmacol Ther. 2020 Oct;108(4):775-790
pubmed: 32438446
Pharmacol Ther. 2020 May;209:107512
pubmed: 32097670
J Infect Dis. 2020 Apr 27;221(10):1688-1698
pubmed: 31822885
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Clin Pharmacol Ther. 2020 Aug;108(2):242-247
pubmed: 32246834
Pharmaceuticals (Basel). 2020 May 14;13(5):
pubmed: 32423024
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11613-11618
pubmed: 30352857
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
J Virus Erad. 2020 Apr 30;6(2):45-51
pubmed: 32405421
Antiviral Res. 2013 Nov;100(2):446-54
pubmed: 24084488
PLoS Med. 2016 Mar 01;13(3):e1001967
pubmed: 26930627
J Virol. 2013 Apr;87(7):3741-51
pubmed: 23325689
Clin Pharmacol Ther. 2020 Aug;108(2):190
pubmed: 32353191
Lancet Glob Health. 2020 May;8(5):e639-e640
pubmed: 32199468
J Clin Pharmacol. 2004 Jan;44(1):7-19
pubmed: 14681337